Clinical Trials

Offices

For This Service

To learn more, please call our Research Department at (513) 936-5388 or (888) 649-4800. Or email abradley@ohcmail.com

  • NEOADJUVANT
     
      
     
     
  • ADJUVANT
         Study number:
                    BRE 177 Amgen 20060359
         Protocol title:
                    A Randomzed, Double-blind, Placebo-Controlled, Multi-Center
                    Phase 3 Study of Dennosumab as Adjuvant Treatment for women
                    with Early-stage Breast Cancer at High Risk of Recurrence
                    (D-CARE)
         Status:
                    Open
    Study number:
    BRE 163   B-46-I/07132 USO/NSABP
    Protocol title:
    Phase III Clinical Trial Comparing the Combination of TC Plus Bevacixumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative Early Breast Cancer
    Status:
    Open 
            Study number:
                     BRE 179 Celldex Therapeutics CDX011-03
            Protocol title:
                     A Phase II, Randomized, Multicenter Study of CDX-011 in Patients
                     with Advanced GPNMB-Expressing Breast Cancer
            Status:
                     Open
     
  • LOCALLY ADVANCED/METASTATIC, FIRST LINE, HER2-
    Study number:
    BRE 138  SCRI
    Protocol title:
    Phase I/II  Trial of Sorafenib Plus Ixabepilone as First-Line Treatment for Patients with HER2-Negative Metastatic Breast Cancer 
    Status:
             Open    
 
 
  • METASTATIC, FIRST LINE, HER2+
    Study number:
    BRE 171  Hoffmann-LaRoche Inc.B022589B/TDM 4788g B-ROW 
    Protocol title:
    A Randomized, 3 ARM, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of T-DM1 Combined with Pertuzumab or T-DM1 Combined with Pertuzumab or Placebo, Versus the Combination of Herceptin plus taxane, as First-line Treatment in HER2 Positive Progressive or Recurrent Locally Advanced or Metastatic Breast Cancer 
    Status:
    Open
     
  • Locally advanced/Metastatic after Taxane and Doxorubicin 
    Study number:
    BRE 183  ImClone Systems, Inc.  IMCL CP20-0903
    Protocol title:
     An Open Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC1121B) Drug Product or IMC18F in Combination with Capecitabine or Capecitabine Monotherapy, in Unrespectable, Locally-advanced or Metastatic Breast Cancer Patients Previously Treated with Anthracycline and Taxane Therapy
    Status:
    Open
     
     
  • METASTATIC OBSERVATIONAL
    Study number:
    BRE 150 AVF4349n Genentech, Inc.
    Protocol title:
    An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer
    Status:
    Open

      

  • RADIATION
    Study number:
    NSABP B-39
    Protocol title:
    A Randomized Phase 3 Study of Conventional Whole Breast Irradiation (WBI) versus Partial Breast Irradiation (PBI) for Women w/Stage 0,I or II Breast Cancer
    Status:
    Open